Sanofi-Aventis U.S. LLC is brandishing a recent U.S. Supreme Court decision to take aim at actions brought by nearly 70 women over its chemotherapy drug Taxotere.
The lawsuits are among more than 1,000 coordinated in federal court in New Orleans alleging that Taxotere, used to treat breast cancer, has caused women to lose their hair permanently. On Thursday, Sanofi filed notices citing the Supreme Court’s June 19 ruling in Bristol-Myers Squibb v. Superior Court of California to oppose the remand of 11 lawsuits to state courts in Missouri and California. In Bristol-Myers, the Supreme Court found that plaintiffs suing in California state court, most of whom weren’t from California, had failed to establish specific jurisdiction against New York-based Bristol-Myers Squibb.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
